Abstract: The invention relates to novel 4-azaandrostene intermediates of formula (I), ##STR1## wherein R is hydrogen or a C.sub.1-3 alkyl group;X is chlorine, bromine or iodine; and the---- bond line is a single or double bond.

Abstract: The invention relates to novel 17.beta.-substituted 4-azaandrostane derivatives of general formula (I), ##STR1## wherein R means hydrogen or a C.sub.1-3 alkyl group;R.sup.1 and R.sup.2 are the same or different and stand for hydrogen or a C.sub.1-4 alkyl group with the proviso that both can mean hydrogen only in the case when n is higher than 5; orR.sup.1 and R.sup.2 together means an .alpha.,.omega.-alkylene group containing 5 to 7 carbon atoms, the terminal carbon atoms of said alkylene group being bound to the same ring carbon atom;n is 4, 5, 6 or 7; and--- bond line represents a single or double bond.Furthermore, the invention relates to pharmaceutical composition containing these compounds as well as a process for the preparation of the compounds of general formula (I).The compounds of general formula (I) exert a 5.alpha.

Abstract: The invention relates to a combination useful for the substitution of bone defects having pathologically developed or being artificially established as well as compositions containing these combinations. The combinations of the invention preferably contain in a weight ratio of 1:9 to 9:1, most preferably 1:1 porous hydroxylapatite and/or tricalcium phosphate in relation to 7-isopropoxyisoflavone.

Abstract: A composition is disclosed for controlling the stimulation of estrogen production, which comprises:(a) 15 to 120 parts by weight of one or more phytoestrogen compounds calculated as a free aglycon form of isoflavone;(b) up to 75 parts by weight of dried licorice root extract;(c) 10 to 80 parts by weight of a sedative selected from the group consisting of Valerian root dry extract, passion flower dry extract, and Ginseng root powder;(d) up to 50, preferably 10 to 20 parts by weight of beta-carotene;(e) up to 200, preferably 15 to 150 parts by weight of pyridoxine hydrochloride;(f) up to 50, preferably 12 to 30 parts by weight of Vitamin E;(g) up to 600, preferably 100 to 450 parts by weight of calcium contained in a biologically acceptable calcium salt;(h) up to 200, preferably 150 to 250 parts by weight of magnesium contained in a biologically acceptable magnesium salt;(i) up to 100, preferably 10 to 50 parts by weight of zinc contained in a biologically acceptable zinc salt;(j) up to 30 parts by weight of co

Abstract: Complexes of deprotonated hyaluronic acid with 3d metal ions of the 4th period of the Periodic Table and compositions containing these complexes as active ingredients or carriers. A process for the preparation of the complexes and compositions (pharmaceutical and cosmetic compositions) containing these complexes as active ingredients are disclosed in which zinc hyaluronate is preferably used as active ingredient.

Abstract: An intermediate compound is disclosed that is useful in the preparation of a lipid-peroxidation inhibiting substance and that is selected from the group consisting of:2,4-bis[1-adamantylamino]-6-(1-piperazinyl)pyrimidine; and4,6-bis(1-adamantylamino)-2-(1-piperazinyl)pyrimidine;or a pharmaceutically acceptable acid addition salt thereof.

Abstract: Novel, therapeutically active 21-aminosteroids of formula (I) ##STR1## with pregnane skeleton, are disclosed wherein two of X, Y and Z are a nitrogen atom each and the third one is a methine group; R.sup.1 and R.sup.2 are independently from each other, a primary amino group bearing as substituent a branched-chain C.sub.4-8 alkyl -alkenyl or -alkynyl group, or a C.sub.4-10 cycloalkyl group comprising 1 to 3 ring(s) and being optionally substituted by at least one C.sub.1-3 alkyl group; or R.sup.1 and R.sup.2 are each a spiro-heterocyclic secondary amino group containing at most 10 carbon atoms and optionally at least one oxygen atom as additional heteroatom; or one of R.sup.1 and R.sup.2 is an unsubstituted heterocyclic secondary amino group containing 4 to 7 carbon atoms and the other one is an above-identified primary amino group, an above-identified spiro-heterocyclic secondary amino group, or a heterocyclic secondary amino group containing 4 to 7 carbon atoms and substituted by at least one C.sub.

Abstract: A solid, non-hygroscopic salt of the Formula (I) ##STR1## wherein R.sup.1 is hydroxy or alkyl;A is C.sub.1 to C.sub.

Abstract: A vaccine is disclosed for the prophylaxis against pathogenic development of atherosclerotic plaque in a mammalian subject susceptible thereto which comprises:(a) 10 to 30% by weight of the compound ##STR1## (b) 10 to 30% by weight of the compound ##STR2## (c) 10 to 30% by weight of the compound ##STR3## (d) 10 to 30% by weight of the compound ##STR4## in combination with a pharmaceutically acceptable inert carrier.

Abstract: A keto ester reductase capable of being used in an NADH-dependent enzymatic reaction for converting .beta., .gamma. and .delta. ketonic acid esters into the corresponding optically active .beta., .gamma. and .delta. hydroxycarboxylic acid esters can be isolated from strains of Candida parapsilosis, Yarrowinia cellobiosa, Rhodococcus erythropolis or Pseudomonas acidovorans, preferably cultivated on a long -chain alkane and/or alkane acid-containing culture medium, approximately in the presence of an inductor. The microorganism is preferrably, Candida parapsilosis DSM 70125. A usable enzyme preparation can be recovered by fractionated PEG-precipitation from the cell raw extract: high specific activities (for example 1855 U/mg) may then be obtained by chromatographic purification.

Abstract: A method is disclosed for detecting abnormal epitope expression of protein molecules by immunocapturing a constant number of protein molecules from a test and a reference sample using a limited amount of capturing antibodies, saturating them with its corresponding protein from the test and reference samples to provide a constant, known amount of the immobilized protein for comparison, labelling an epitope on the immobilized protein by means of a labelled probing antibody specifically reactive with the epitope and correlating any difference in labelling between the test and the reference sample to the absence or modification of the epitope in the protein of the test sample.

Abstract: A composite body, especially for use as a cutting tool, for the lining of combustion chambers or for movable parts intended to have low wear which has a substrate of hard metal, steel, cermet or nickel or cobalt alloy. The substrate is provided with at least one fine-crystalline alpha-Al.sub.2 O.sub.3 layer deposited by plasma activated CVD at 400.degree. to 750.degree. C. With plasma activation by pulsed direct voltage with the substrate connected as the cathode.

Abstract: The invention relates to novel eburnamenine derivatives of formula (I): ##STR1## wherein R.sup.1 and R.sup.2 as well as R.sup.3 and R.sup.4, independently from each other, stand for hydrogen, C.sub.2-6 alkyl group, C.sub.2-6 alkenyl group; or a C.sub.3-10 alicyclic group involving 1 to 3 rings, and this latter group may be substituted by a C.sub.1-6 alkyl or C.sub.2-6 alkenyl group; or R.sup.1 and R.sup.2 and/or R.sup.3 and R.sup.4, together with the adjacent nitrogen atom and optionally with an additional oxygen or nitrogen atom, form a 4- to 6-membered, saturated or unsaturated cyclic group which may be substituted by a C.sub.1-6 alkyl or C.sub.2-6 alkenyl group; two of X, Y and Z are nitrogen whereas the third of them means a methine group; n is 1 or 2; W means oxygen or two hydrogen atoms; and the wavy line means .alpha.-/.alpha.-, .alpha.-/.beta.- or .beta.-/.alpha.- steric position, as well as their acid addition salts and solvates.

Abstract: This invention refers to a wood substitute with lignocellulosic and mineral material particles which are molded in sheet, e.g. plates and/or panels in different thicknesses or forms in stencil at choice, using in principal natural and artificial, and vegetal cellulosic material components, e.g. dried leaves, sawdust, rotten wood particles splinters, paperwastes, roots and mineral materials as limestone from sulphates type carbonates or calcium oxides, with synthetic binders from different chemical structures, with or without dyes, in these proportions: 35-60 by weight lignocellulosic components particles, 5-35 by weight limestone types, 5-30 by weight synthetic binders from different harmless chemical structures, with or without synthetic dyes from varied chemical structures and with or without requested additions.

Abstract: A process is disclosed for preparing a carbon molecular sieve used for the separation of oxygen from nitrogen, which comprises the steps of:(a) milling hard coal to a grain size of 95%<20.mu.m;(b) oxidizing the finely milled hard coal with air in a fluidized bed;(c) adding water and coal tar pitch as a binder and molding the finely milled hard coal into shape;(d) carbonizing the finely milled hard coal molded into shape in a rotary kiln at a temperature of 500 .degree.to 850.degree. C., with a dwelling time of 55 to 65 minutes, in order to obtain a carbonization product with a bulk density of 530 to 560 g/l;(e) activating the carbonization product with steam at to 900.degree. C. for 165 to 195 minutes to obtain a sintered carbonaceous product having a bulk density of 590 to 650 g/l; and(f) treating the sintered carbonaceous product at 750 to 850.degree. C. with carbon-splitting hydrocarbons to obtain said carbon molecular sieve.

Abstract: New compounds with the ability to inhibit calcium uptake in the brains of mammals are disclosed of the Formula (I) ##STR1## wherein R.sup.1 is hydrogen, C.sub.1 to C.sub.4 alkyl, phenyl, or phenyl-C.sub.1 to C.sub.4 alkyl;one of R.sup.2 and R.sup.3 is C.sub.1 to C.sub.4 alkoxy and the other one is phenyl-C.sub.1 to C.sub.4 alkoxy optionally substituted by C.sub.1 to C.sub.4 alkyl in the aromatic nucleus; andR.sup.4 is phenyl optionally substituted by C.sub.1 to C.sub.4 alkyl in the aromatic nucleus, or their solvates, individual optically active and geometric isomers, mixtures of such isomers, as well as pharmaceutically acceptable acid addition salts thereof. The compounds of the Formula (I) are capable of inhibiting calcium uptake to brain cells and have a protective effect on hypobaric hypoxia.

Abstract: A new and original water paint is disclosed, in liquid form, such as a milky emulsion, containing a low amount of water and comprising minerals, acetic acid solution, and other components. The new water paint has bactericidal, fireproof, transpiring, ecological, isolating and desalting properties and is suitable to coat manufactured building articles, wood, metals and plastic.

Abstract: Match head formulations suitable for the production of safety matches and matches that may be struck anywhere are described in which chromium compounds, sesqui-based phosphorus compounds, sulphur compounds and oxides of zinc are absent. In their place is described the use of either amorphous phosphorus or, in the case of match head formulations suitable for the production of safety matches, an iron phosphade known as ferrophosphorus. These formulations are environmentally friendly both in manufacture and use. Environmentally friendly match head formulations which may be brightly colored are also described.

Abstract: The invention relates to a process for producing thin films in which the pressure of the process gas is kept constant in a process chamber with a gas inlet and outlet, a target and a substrate, while material is sputtered from the target and deposited on the substrate. The invention also relates to a process for producing thin films. It is the purpose of the invention to create a process providing a more homogenous film. According to the invention, to this end the process gas is caused to reach the plasma. Alternatively, either one or several emission lines may be spectroscopically detected in a spatial region and, after a desired cross sectional shape has been set, it is kept constant in time by subsequently regulating the process gas mixing ratio.

Abstract: 4-oxo-4H-pyrido[1,2-a]-pyrimidines are disclosed of the formula ##STR1## wherein R is a C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-6 alkynyl, C.sub.3-7 cycloalkyl, --(CH.sub.2).sub.n --COOR.sup.3 wherein R.sup.3 is C.sub.1 to C.sub.4 alkyl and n is 0 or 1 or a C.sub.7-8 aralkyl group, optionally substituted by one or more halogen atom(s), or by a nitro-group, R.sup.1 is a hydrogen atom or a C.sub.1-4 alkyl group, and salts thereof, as well as a process for their preparation, and pharmaceutical compositions containing them. These compounds are therapeutically useful as gastroprotectives in the treatment and prevention of ulcer.